Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial

PURPOSE: To report the clinical efficacy of sorafenib and to evaluate biomarkers associated with sorafenib clinical benefit in the BATTLE program. PATIENTS AND METHODS: Patients with previously treated non-small–cell lung cancer (NSCLC) received sorafenib until progression or unacceptable toxicity....

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Blumenschein, George R., Saintigny, Pierre, Liu, Suyu, Kim, Edward S., Tsao, Anne S., Herbst, Roy S., Alden, Christine, Lee, J. Jack, Tang, Ximing, Stewart, David J., Kies, Merrill S., Fossella, Frank V., Tran, Hai T., Mao, L., Hicks, Marshall E., Erasmus, Jeremy, Gupta, Sanjay, Girard, Luc, Peyton, Michael, Diao, Lixia, Wang, Jing, Davis, Suzanne E., Minna, John, Wistuba, Ignacio, Hong, Waun K., Heymach, John V., Lippman, Scott M.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2013
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3905243/
https://ncbi.nlm.nih.gov/pubmed/24166906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-1818
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة